Exploring the effect of vitamin D<sub>3</sub> supplementation on the anti-EBV antibody response in relapsing-remitting multiple sclerosis.

Details

Ressource 1Download: 28731372_BIB_FD2BEB7A97DB.pdf (614.92 [Ko])
State: Public
Version: Final published version
License: CC BY-NC 4.0
Serval ID
serval:BIB_FD2BEB7A97DB
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Exploring the effect of vitamin D<sub>3</sub> supplementation on the anti-EBV antibody response in relapsing-remitting multiple sclerosis.
Journal
Multiple sclerosis
Author(s)
Rolf L., Muris A.H., Mathias A., Du Pasquier R., Koneczny I., Disanto G., Kuhle J., Ramagopalan S., Damoiseaux J., Smolders J., Hupperts R.
ISSN
1477-0970 (Electronic)
ISSN-L
1352-4585
Publication state
Published
Issued date
09/2018
Peer-reviewed
Oui
Volume
24
Number
10
Pages
1280-1287
Language
english
Notes
Publication types: Journal Article
Publication Status: ppublish
Abstract
Epstein-Barr virus (EBV) infection and vitamin D insufficiency are potentially interacting risk factors for multiple sclerosis (MS).
To investigate the effect of high-dose vitamin D <sub>3</sub> supplements on antibody levels against the EBV nuclear antigen-1 (EBNA-1) in patients with relapsing-remitting multiple sclerosis (RRMS) and to explore any underlying mechanism affecting anti-EBNA-1 antibody levels.
This study utilized blood samples from a randomized controlled trial in RRMS patients receiving either vitamin D <sub>3</sub> (14,000 IU/day; n = 30) or placebo ( n = 23) over 48 weeks. Circulating levels of 25-hydroxyvitamin-D, and anti-EBNA-1, anti-EBV viral capsid antigen (VCA), and anti-cytomegalovirus (CMV) antibodies were measured. EBV load in leukocytes, EBV-specific cytotoxic T-cell responses, and anti-EBNA-1 antibody production in vitro were also explored.
The median antibody levels against EBNA-1, but not VCA and CMV, significantly reduced in the vitamin D <sub>3</sub> group (526 (368-1683) to 455 (380-1148) U/mL) compared to the placebo group (432 (351-1280) to 429 (297-1290) U/mL; p = 0.023). EBV load and cytotoxic T-cell responses were unaffected. Anti-EBNA-1 antibody levels remained below detection limits in B-cell cultures.
High-dose vitamin D <sub>3</sub> supplementation selectively reduces anti-EBNA-1 antibody levels in RRMS patients. Our exploratory studies do not implicate a promoted immune response against EBV as the underlying mechanism.
Keywords
Antibodies, EBNA-1, Epstein–Barr virus, multiple sclerosis, supplementation, vitamin D
Pubmed
Web of science
Open Access
Yes
Create date
28/08/2017 11:37
Last modification date
20/08/2019 17:28
Usage data